Theravance Biopharma buy klostergang
Start price
01.12.18
/
50%
€25.26
Target price
04.11.21
€34.28
Performance (%)
-41.40%
End price
17.06.21
€14.80
Summary
This prediction ended on 17.06.21 with a price of €14.80. Massive losses of -41.40% were the result for the BUY prediction by klostergang. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Theravance Biopharma | -1.775% | -1.775% | 94.152% | 73.822% |
| iShares Core DAX® | 1.301% | -1.386% | 12.259% | 59.752% |
| iShares Nasdaq 100 | 0.612% | -4.172% | 1.687% | 86.147% |
| iShares Nikkei 225® | 8.772% | 9.777% | 30.041% | 63.047% |
| iShares S&P 500 | 0.254% | -2.301% | 0.794% | 57.981% |
Comments by klostergang for this prediction
In the thread Theravance Biopharma diskutieren
klostergang stimmt der Buy-Einschätzung von marge zu
klostergang stimmt am 01.12.2018 der Buy-Einschätzung von marge mit dem Kursziel 55$ zu.
Überschrift: TBPH: Revefenacin for Chronic Obstructive Pulmonary disease [COPD]